PPT-Warfarin Therapy

Nicolas Novitzky The Ideal Oral Anticoagulant Ideally an oral anticoagulant would Have high efficacy in reducing thromboembolic events Reach therapeutic levels within several hours Oral. Geoffrey Barnes, MD. Cardiovascular and Vascular Medicine. University of Michigan, USA. 1. st. Qatar Conference on . Safe Anticoagulation Management. February 27, 2015. Outline. VTE Recurrence Risk. , MD, PhD . Monday Morning Conference. Oct 4, 2010. Rivaroxaban. Dabigatran. Classes. Unfractionated. heparin. Direct thrombin inhibitors. Low molecular weight heparins, . fondiparinux. Vitamin K antagonists, Inhibiting clotting factors: II, VII, IX, X. CHEST Guidelines 2016. Jennifer . Mah. , MD. March 2016. Case. A 44-year-old man is evaluated in follow-up for an episode of unprovoked left proximal leg deep venous thrombosis 3 months ago. Following initial anticoagulation with low-molecular-weight heparin, he began treatment with . warfarin. Patient profile. -. ผู้ป่วยชายไทยคู่. -. มาพบแพทย์ตามนัด. -good compliance. -no complication. -. โรคประจำตัว. Advantages of NOACs. No INR monitoring required. No bridging required . Easier to manage around surgical procedures. Convenient for rural patients or those with other barriers to . clinic . visits. Fewer. Antithrombotic therapy and oral surgery Michael B Streiff, MD FACP Professor of Medicine and Pathology Medical Director, Johns Hopkins Anticoagulation Service Chairman, VTE Guideline Committee ,National Comprehensive Cancer Network www.onlinecjc.com. ). .  . If your reuse request qualifies as medical institution internal education, you may reuse the material under the following conditions:. You must cite the Canadian Journal of Cardiology and the Canadian Cardiovascular Society as references.. Indication and Target INRAtrial Fibrillation / Atrial Flutter INR 23 Goal 25Stroke INR 23 Goal 25Mechanical ValveAortic Position INR 23 Goal 2Aortic PositionMitral Position INR 2535 Goal 3 OtherPos September 2017. Promoting Anticoagulation . Safety. An . update on the use of newer . anticoagulants and . antiplatelet therapy. Learning Objectives. Evaluate the proper use of oral anticoagulants and antiplatelet medications (e.g., indications, dosing, monitoring). Assoc. iate. . . Prof Tatjana Šimurina MD, PhD. General Hospital Zadar; . Dept. .. . of Health Study, University of Zadar; . Assist Prof - Medical faculty, University of Osijek . tsimurina@unizd.hr. Received January 25, 1999, from the Department of Obstetrics andGynecology, Faculty of Medicine, Chiang Mai University, ChiangMai, Thailand. Revised manuscript accepted for publication April 4,Address 1 COUMADIN Tablets for oralLactose, starch and magnesium stearate 1 mg: D&C Red No. 6 Barium Lake 2 mg: FD&C Blue No. 2 Aluminum Lake and FD&C Red No. 40 Aluminum Lake 2-1/2 mg: D&C Yellow No. 10 Therapy Training. 03/10/2015. Objectives. 1. What is an . anticoagulant. . ?. 2. Why is anticoagulant therapy necessary?. 3. What is a PT/INR?. 4. Who can give Warfarin sodium?. Heart. Pumps blood through the body. Oliguria. Hypoxia. Tachycardia. Cover Shifts part 3 - Dr Carol Chong. What meds are in your armamentarium?. Constipation. 1/7 of constipation. Coloxyl. and . senna. 2 tablets . b.d. +. Lactulose. 20mls o .